Center for Human Reproduction Company

A self-styled “fertility clinic of last resort”, the Center for Human Reproduction is a leading fertility center located in New York City. They specialise in “older” ovary rejuvenation, whether due to advanced female age or premature ovarian aging (POA), immunological problems affecting reproduction, repeated pregnancy loss, endometriosis, polycystic ovary syndrome (PCOS), tubal disease, male factor infertility, etc. "Firsts" developed at CHR included the idea of vaginal egg retrieval, which was performed at CHR for the first time and published in the reputable medical journal The Lancet. CHR investigators also pioneered the concept of tubal catheterization to recanalize obstructed fallopian tubes, first published in the prestigious journal JAMA. The most influential recent contribution of CHR research to infertility treatment was the introduction of supplementation with DHEA in women with poor ovarian reserve. CHR’s physicians and scientists are well recognized by peers all over the world, because of the center’s large number of scientific publications and clinical outcomes.

Headquarters: New York, New York, United States
Funding Status: N/A
Employee Number: N/A
Investment Stage: N/A
Number Of Exists: N/A
Technology: Biotechnology, Health Care, Medical, Non Profit
Investor Type: N/A
Founded Date: N/A
Industry: Longevity